The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guideline as well as the American Diabetes Association 2022 guideline advise using ≥30 mg/day finerenone in patients with albuminuria despite being on a combination of ACE inhibitor and SGLT-2 inhibitor [38]. Here, SLC5A2 is linked to kidney disorder.